Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics (VERV)
NASDAQ:VERV
RESEARCH TOOLSreports
Holding VERV?
Track your performance easily
VERV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.31 - $19.34
Previous CloseN/A
Volume257.30K
Average Volume (3M)1.49M
Market Cap
$516.45M
Enterprise Value-$59.04M
Total Cash (Recent Filing)$18.78M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.24
Next Earnings
Feb 26, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.46
Shares Outstanding84,663,840
10 Day Avg. Volume1,368,132
30 Day Avg. Volume1,488,342
Standard Deviation0.26
R-Squared0.10
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)19.05
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.11
Enterprise Value/Revenue-3.37
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$21.40Price Target Upside250.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Verve Therapeutics News
PremiumCompany Announcements
Verve Therapeutics Reports Q3 Progress and Financials
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe successful dosing of 7 patients at 2 dose levels in the Heart-2 trial with no serious adverse events is a positive indication.
Financial PerformanceVerve closes Q2 with $575.9M on the balance sheet, which carries runway into late-2026 and through key clinical data readouts in 2025.
Market OpportunityVerve announced the dosing of the first patient in the Pulse-1 Phase 1b clinical trial with VERVE-201, which presents a more enticing commercial opportunity with a significantly larger and growing target market.
Bears Say
Financial PerformanceIn Q2 2024, Verve reported a net loss of $49.8M, or $0.59/share, as compared to $54.0M, or $0.87/share, over the same period in 2023.
Price TargetDecreasing the price target to $29 from $30 based on increased shares outstanding.
Short InterestShort interest is reported at 27.9% of the float.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VERV FAQ
What was Verve Therapeutics’s price range in the past 12 months?
Verve Therapeutics lowest stock price was $4.30 and its highest was $19.34 in the past 12 months.
What is Verve Therapeutics’s market cap?
Verve Therapeutics’s market cap is $516.45M.
When is Verve Therapeutics’s upcoming earnings report date?
Verve Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is in 39 days.
How were Verve Therapeutics’s earnings last quarter?
Verve Therapeutics released its earnings results on Nov 05, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.684 by $0.094.
Is Verve Therapeutics overvalued?
According to Wall Street analysts Verve Therapeutics’s price is currently Undervalued.
Does Verve Therapeutics pay dividends?
Verve Therapeutics does not currently pay dividends.
What is Verve Therapeutics’s EPS estimate?
Verve Therapeutics’s EPS estimate is -0.68.
How many shares outstanding does Verve Therapeutics have?
Verve Therapeutics has 84,663,840 shares outstanding.
What happened to Verve Therapeutics’s price movement after its last earnings report?
Verve Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.684. Following the earnings report the stock price went up 5.455%.
Which hedge fund is a major shareholder of Verve Therapeutics?
Among the largest hedge funds holding Verve Therapeutics’s share is Baker Bros Advisors LP. It holds Verve Therapeutics’s shares valued at 8M.
---
Verve Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.40 (250.82% Upside)
$21.40 (250.82% Upside)
Blogger Sentiment
Bullish
VERV Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-51.35%
12-Months-Change
Fundamentals
Return on Equity
-40.67%
Trailing 12-Months
Asset Growth
8.41%
Trailing 12-Months
Company Description
Verve Therapeutics
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
---
VERV Stock 12 Month Forecast
Average Price Target
$21.40
▲(250.82% Upside)
Technical Analysis
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Beam Therapeutics
―
RegenXBio
―
Sangamo Biosciences
―
Best Analysts Covering VERV
1 Year
1 Year Success Rate
2/16 ratings generated profit
1 Year Average Return
-32.47%
reiterated a buy rating 2 months ago
Copying Luca Issi's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -32.47% per trade.
---